Loading...
Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.
Abdelsamie, Ahmed S Bey, Emmanuel Hanke, Nina Hartmann, Rolf W Frotscher, Martin
Abdelsamie, Ahmed S
Bey, Emmanuel
Hanke, Nina
Hartmann, Rolf W
Frotscher, Martin
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2014-07-23
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 820.58 KB
Loading...
supporting information
Adobe PDF, 5.35 MB
Other Titles
Abstract
Estradiol is the most potent estrogen in humans. It is known to be involved in the development and proliferation of estrogen dependent diseases such as breast cancer and endometriosis. The last step of its biosynthesis is catalyzed by 17β-hydroxysteroid dehydrogenase type 1 (17β- HSD1) which consequently is a promising target for the treatment of these diseases. Recently, we reported on bicyclic substituted hydroxyphenylmethanones as potent inhibitors of 17β-HSD1. The present study focuses on rational structural modifications in this compound class with the aim of gaining more insight into its structure-activity relationship (SAR). (4-Hydroxyphenyl)-(5-(3-hydroxyphenylsulfanyl)-thiophen-2-yl)methanone (25) was discovered as a member of a novel potent class of human 17β-HSD1 inhibitors. Computational methods were used to elucidate its interactions with the target protein. The compound showed activity also towards the murine 17β-HSD1 enzyme and thus is a starting point for the design of compounds suitable for evaluation in an animal disease model.
Citation
Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker. 2014, 82:394-406 Eur J Med Chem
Affiliation
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1768-3254
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to European journal of medicinal chemistry